Cancer in France – Protontherapy
Figures for cancer in France
new cases :
355,000 new cases of cancer were estimated for 2012, 200,000 men and 155,000 women.
The average age of diagnosis is 68 in men and 67 in women.
Mortality :
Cancer mortality has decreased over the last twenty years. However cancer is the leading cause of death in France.
In 2012, it was estimated that there were 148,000 deaths from cancer: 85,000 men and 63,000 women. In men, lung cancer is the main cause of death, followed by colorectal and prostate cancers. In women, it is breast cancer followed by colorectal and lung cancers.
Survival rates :
5-year survival rates depend on the type of cancer (6 to 95%).
Most common cancers in men :
- prostate (53,000 cases – 2009 data)
- lung (27,000)
- colorectal (21,000)
Most common cancers in women :
- breast (52,500 cases)
- colorectal (19,000)
- lung (10,000)
2012 data
(Source : Institut national du Cancer: © Le cancer en France en 2013)
RESEARCH :
Cancer research France is collaborative by definition. Researchers at the Institut Curie often join forces with colleagues at French institutions and, more broadly, on an international scale. This open-minded approach is very much the norm at Institut Curie.
The Research Center at Institut Curie is part of a rich environment in which it has developed numerous ties with universities and institutions to increase its sphere of influence, pool its resources and expertise, and strengthen its strategic position. It is supported by its institutional and university authorities and by industry.
The Centre de Protonthérapie at Institut Curie offers an ultra-precise form of radiotherapy used to treat certain adult and childhood cancers. This level of precision requires cutting-edge equipment along with an expert team.
Proton therapy is an ultra-precise form of radiotherapy, radiating tumors with high precision while protecting the healthy organs close to the tumor. This ultra-precise technology is indicated for treating children in particular, since it comes with a lower risk of side-effects, as well as for certain adult cancers such as eye tumors.
